Biotechnology major Biocon today reported a 54.51 per cent decline in its consolidated net profit at Rs 113.08 crore for the fourth quarter of the last financial year.
The company had posted a net profit of Rs 248.61 crore in the same period of 2012-13, which the company attributed to one-time exceptional income.
"The 55 per cent down is only when we look at it in terms of exceptional income; exceptional income is the one-time exceptional income that we booked last year....," Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said
Also Read
"There was Rs 202 crore of exceptional one-time income booked last year....We had actually booked before expenditure from a deal which we made with Pfizer a long time ago, and when we actually licensed the same asset with Mylan we then took some of that into profit. So, it should not be viewed in that way that's an exceptional income and has nothing to do with operating income."
The company said that its PAT (adjusted for the exceptional income) for the period under review is up by 75 per cent.
Net sales rose to Rs 722.59 crore for the fourth quarter as against Rs 630.12 crore for the same period a year ago.
For the year ended March 31, 2014, the company's net profit declined by 18.69 per cent to Rs 413.72 crore from Rs 508.82 crore in the 2012-13 fiscal.
However, PAT (adjusted for the exceptional income) for the year ended on March 31 is up by 28 per cent.
The company's net sales for the just-concluded fiscal rose to Rs 2,852.72 crore, as against Rs 2,427.60 crore in the previous year.
The company's board also recommended a 100 per cent dividend of Rs 5 per share.
